Rg3 in Combination With TACE in Hepatocellular Carcinoma Patients With High Expression of Notch1

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

In order to provide a new option for clinical anti-angiogenesis therapy in hepatoma, a randomized controlled study is planed to confirm the effect of Rg3 in combination with TACE on angiogenesis and tumor treatment in advanced hepatocellular carcinoma patients with high expression of Notch1.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eastern Hepatobiliary Surgery Hospital
• Treatments: Chlorotrianisene

Criteria

Inclusion Criteria:

1. Pathologically confirmed hepatocellular carcinoma.

2. High expression of Notch1 in tumor tissues.

Exclusion Criteria:

no pathological evidence of HCC